BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Joshi S. Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions. Cancers (Basel) 2020;12:E2057. [PMID: 32722460 DOI: 10.3390/cancers12082057] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Mhaidly R, Mechta-grigoriou F. Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies. Seminars in Immunology 2020;48:101417. [DOI: 10.1016/j.smim.2020.101417] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
2 Shim J, Goldsmith KC. A New Player in Neuroblastoma: YAP and Its Role in the Neuroblastoma Microenvironment. Cancers (Basel) 2021;13:4650. [PMID: 34572875 DOI: 10.3390/cancers13184650] [Reference Citation Analysis]
3 Ferrada L, Barahona MJ, Salazar K, Godoy AS, Vera M, Nualart F. Pharmacological targets for the induction of ferroptosis: Focus on Neuroblastoma and Glioblastoma. Front Oncol 2022;12:858480. [DOI: 10.3389/fonc.2022.858480] [Reference Citation Analysis]
4 Liu KX, Joshi S. "Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma. Front Immunol 2020;11:1947. [PMID: 32983125 DOI: 10.3389/fimmu.2020.01947] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
5 Ishfaq M, Pham T, Beaman C, Tamayo P, Yu AL, Joshi S. BTK Inhibition Reverses MDSC-Mediated Immunosuppression and Enhances Response to Anti-PDL1 Therapy in Neuroblastoma. Cancers (Basel) 2021;13:817. [PMID: 33669187 DOI: 10.3390/cancers13040817] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mokhtari RB, Sambi M, Qorri B, Baluch N, Ashayeri N, Kumar S, Cheng HM, Yeger H, Das B, Szewczuk MR. The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. Cancers (Basel) 2021;13:3596. [PMID: 34298809 DOI: 10.3390/cancers13143596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ciaccio R, De Rosa P, Aloisi S, Viggiano M, Cimadom L, Zadran SK, Perini G, Milazzo G. Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs. Int J Mol Sci 2021;22:12883. [PMID: 34884690 DOI: 10.3390/ijms222312883] [Reference Citation Analysis]
8 Uva P, Bosco MC, Eva A, Conte M, Garaventa A, Amoroso L, Cangelosi D. Connectivity Map Analysis Indicates PI3K/Akt/mTOR Inhibitors as Potential Anti-Hypoxia Drugs in Neuroblastoma. Cancers (Basel) 2021;13:2809. [PMID: 34199959 DOI: 10.3390/cancers13112809] [Reference Citation Analysis]
9 Ollauri-Ibáñez C, Astigarraga I. Use of Antiangiogenic Therapies in Pediatric Solid Tumors. Cancers (Basel) 2021;13:E253. [PMID: 33445470 DOI: 10.3390/cancers13020253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 López-Carrasco A, Martín-Vañó S, Burgos-Panadero R, Monferrer E, Berbegall AP, Fernández-Blanco B, Navarro S, Noguera R. Impact of extracellular matrix stiffness on genomic heterogeneity in MYCN-amplified neuroblastoma cell line. J Exp Clin Cancer Res 2020;39:226. [PMID: 33109237 DOI: 10.1186/s13046-020-01729-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
11 Luo B, Wang L, Gao W, Su Y, Lu Y, Zheng J, Yin J, Zhao Q, Li J, Da Y, Li L. Using a Gene Network of Pyroptosis to Quantify the Responses to Immunotherapy and Prognosis for Neuroblastoma Patients. Front Immunol 2022;13:845757. [DOI: 10.3389/fimmu.2022.845757] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhou Y, Yan H, Zhou Q, Feng R, Wang P, Yang F, Zhang Y, Yuan Z, Zhai B. Beta-Lapachone Attenuates BMSC-Mediated Neuroblastoma Malignant Transformation by Inhibiting Gal-3/Gal-3BP/IL6 Axis. Front Pharmacol 2021;12:766909. [PMID: 34790130 DOI: 10.3389/fphar.2021.766909] [Reference Citation Analysis]
13 Ning L, Shim J, Tomov ML, Liu R, Mehta R, Mingee A, Hwang B, Jin L, Mantalaris A, Xu C, Mahmoudi M, Goldsmith KC, Serpooshan V. A 3D Bioprinted in vitro Model of Neuroblastoma Recapitulates Dynamic Tumor-Endothelial Cell Interactions Contributing to Solid Tumor Aggressive Behavior. Adv Sci (Weinh) 2022;:e2200244. [PMID: 35644929 DOI: 10.1002/advs.202200244] [Reference Citation Analysis]
14 Onyeisi JOS, Lopes CC, Götte M. Syndecan-4 as a Pathogenesis Factor and Therapeutic Target in Cancer. Biomolecules 2021;11:503. [PMID: 33810567 DOI: 10.3390/biom11040503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Sha Y, Han L, Sun B, Zhao Q. Identification of a Glycosyltransferase Signature for Predicting Prognosis and Immune Microenvironment in Neuroblastoma. Front Cell Dev Biol 2021;9:769580. [PMID: 35071226 DOI: 10.3389/fcell.2021.769580] [Reference Citation Analysis]
16 Desbois M, Wang Y. Cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironment. Immunol Rev 2021;302:241-58. [PMID: 34075584 DOI: 10.1111/imr.12982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
17 Miao L, Zhuo Z, Tang J, Huang X, Liu J, Wang HY, Xia H, He J. FABP4 deactivates NF-κB-IL1α pathway by ubiquitinating ATPB in tumor-associated macrophages and promotes neuroblastoma progression. Clin Transl Med 2021;11:e395. [PMID: 33931964 DOI: 10.1002/ctm2.395] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]